

Resource Summary Report

Generated by [dkNET](#) on Aug 3, 2026

Brilliant Violet 570(TM) anti-human CD20

RRID:AB_2563805

Type: Antibody

Proper Citation

BioLegend Cat# 302332, RRID:AB_2563805

Antibody Information

URL: http://antibodyregistry.org/AB_2563805

Proper Citation: BioLegend Cat# 302332, RRID:AB_2563805

Target Antigen: CD20

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 570(TM) anti-human CD20

Description: This monoclonal targets CD20

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone 2H7

Antibody ID: AB_2563805

Vendor: BioLegend

Catalog Number: 302332

Alternative Catalog Numbers: 302331

Record Creation Time: 20250820T060334+0000

Record Last Update: 20250820T231133+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 570(TM) anti-human CD20.

No alerts have been found for Brilliant Violet 570(TM) anti-human CD20.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Ma KM, et al. (2025) HIV broadly neutralizing antibody precursors to the Apex epitope induced in nonhuman primates. *Science immunology*, 10(110), eadt6660.

Ols S, et al. (2023) Multivalent antigen display on nanoparticle immunogens increases B cell clonotype diversity and neutralization breadth to pneumoviruses. *Immunity*, 56(10), 2425.

Oyler BL, et al. (2023) Multilevel human secondary lymphoid immune system compartmentalization revealed by complementary imaging approaches. *iScience*, 26(8), 107261.

Darrah PA, et al. (2023) Airway T_H17 cells are a correlate of i.v. Bacille Calmette-Guerin-mediated protection against tuberculosis in rhesus macaques. *Cell host & microbe*, 31(6), 962.

Gagne M, et al. (2022) Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. *Cell*, 185(1), 113.

Gagne M, et al. (2022) mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. *Cell*, 185(9), 1556.

Nganou-Makamdop K, et al. (2021) Translocated microbiome composition determines immunological outcome in treated HIV infection. *Cell*, 184(15), 3899.

Glaros V, et al. (2021) Limited access to antigen drives generation of early B cell memory while restraining the plasmablast response. *Immunity*, 54(9), 2005.

Harrington WE, et al. (2021) Rapid decline of neutralizing antibodies is associated with decay of IgM in adults recovered from mild COVID-19. *Cell reports. Medicine*, 2(4), 100253.

Shangguan S, et al. (2021) Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection

against HIV-1. *eLife*, 10.

Townsley SM, et al. (2021) B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodies. *Cell host & microbe*, 29(4), 564.

Townsley SM, et al. (2021) Sequential staining of HIV gp140 to capture antigen-specific human B cells via flow cytometry. *STAR protocols*, 2(3), 100771.

Ols S, et al. (2020) Route of Vaccine Administration Alters Antigen Trafficking but Not Innate or Adaptive Immunity. *Cell reports*, 30(12), 3964.

Cirelli KM, et al. (2019) Slow Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance. *Cell*, 177(5), 1153.